Abstract
Ototoxicity can be defined as an adverse reaction of the inner ear or auditory nerve, characterized by cochlear and vestibular dysfunction when exposed to certain pharmacological agents. Ototoxicity can be further divided into cochlear toxicity or vestibular toxicity, depending on which symptoms are dominant. Both cochlear and vestibular toxicity are not exclusively independent of each other. Elements of cochlear toxicity, such as sensorineural hearing loss and tinnitus, can be present even if the patient complains of severe, disabling vestibular symptoms.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Handelsman JA. Vestibulotoxicity: strategies for clinical diagnosis and rehabilitation. Int J Audiol. 2018;57(sup4):S69–77. https://doi.org/10.1080/14992027.2018.1468092.
Black FE, Pesznecker SC. Vestibular ototoxicity. Clinical considerations. Otolayngol Clin N Am. 1993;26(5):713–36.
Black FO, Gianna-Poulin C, Pesznecker SC. Recovery from vestibular ototoxicity. Otol Neurotol. 2001;22(5):662–71. https://doi.org/10.1097/00129492-200109000-00018.
Ganesan P, Schmiedge J, Manchaiah V, Swapna S, Dhandayutham S, Kothandaraman PP. Ototoxicity: a challenge in diagnosis and treatment. J Audiol Otol. 2018;22(2):59–68. https://doi.org/10.7874/jao.2017.00360. Epub 2018 Feb 26. PMID: 29471610; PMCID: PMC5894487.
Llorens J, Callejo A, Greguske EA, Maroto AF, Cutillas B, Martins-Lopes V. Physiological assessment of vestibular function and toxicity in humans and animals. Neurotoxicology. 2018;66:204–12. https://doi.org/10.1016/j.neuro.2018.02.003. Epub 2018 Feb 8. PMID: 29428870.
Longridge NS, Mallinson AI. The dynamic illegible E (DIE) test: a simple technique for assessing the ability of the vestibular ocular reflex to overcome vestibular pathology. J Otolaryngol. 1987;16:97–100.
Halmagyi GM, Curthoys IS. A clinical sign of canal paresis. Arch Neurol. 1988;45:737.
Guyot JP, Perez Fornos A. Milestones in the development of a vestibular implant. Curr Opin Neurol. 2019;32(1):145–53. https://doi.org/10.1097/WCO.0000000000000639.
Guyot JP, Guinand N, Perez Fornos A. Tribute to Bernard Cohen - whose pioneering work made the vestibular implant possible. Front Neurol. 2020;11:452. https://doi.org/10.3389/fneur.2020.00452.
Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, et al. CPNDS. Consortium genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet. 2009;41:1345–9.
Choeyprasert W, Sawangpanich R, Lertsukprasert K, Udomsubpayakul U, Songdej D, Unurathapan U, et al. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms. J Pediatr Hematol Oncol. 2013;35:e138.
Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol. 2007;25:708–14.
Palodetto B, Postal M, Grignoli CR, Sartorato EL, Oliveira CA. Influence of glutathione s transferase on the ototoxicity caused by aminoglycosides. Braz J Otorhinolaryngol. 2010;76:306–9.
Peters U, Preisler-Adams S, Hebeisen A, Hahn M, Seifert E, Lanvers C, et al. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000;11:639–43.
Pussegoda K, Ross CJ, Visscher H, Yazdanpanah M, Brooks B, Rassekh SR, et al. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther. 2013;94:243–51.
Riedemann L, Lanvers C, Deuster D, Peters U, Boos J, Jürgens H, et al. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J. 2008;8:23–8.
Yang JJ, Lim JY, Huang J, Bass J, Wu J, Wang C, et al. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther. 2013;94:252–9.
Fernandez K, Wafa T, Fitzgerald TS, Cunningham LL. An optimized, clinically relevant mouse model of cisplatin-induced ototoxicity. Hear Res. 2019;375:66–74. https://doi.org/10.1016/j.heares.2019.02.006. Epub 2019 Feb 22.
Hagleitner MM, Coenen MJ, Patino-Garcia A, de Bont ES, Gonzalez-Neira A, Vos HI, et al. Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts. PLoS One. 2014;9:e115869.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
de Souza, C., de Souza, R., Patil, A. (2023). Vestibular Ototoxicity. In: Crane, B.T., Lustig, L., de Souza, C. (eds) Disorders of the Vestibular System. Springer, Cham. https://doi.org/10.1007/978-3-031-40524-2_9
Download citation
DOI: https://doi.org/10.1007/978-3-031-40524-2_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-40523-5
Online ISBN: 978-3-031-40524-2
eBook Packages: MedicineMedicine (R0)